Invasive and non-invasive prognostic markers – What to trust and how to optimize surveillance after heart transplantation
Heart transplantation (HTx) remains the ultimate treatment for selected end-stage heart failure patients. Over time, patient selection and pre- and post-operative management have improved along with immunosuppressive therapy. However, these efforts have failed to improve outcome following the first post-transplant year. Analysis of International Society for Heart and Lung Transplantation registry data shows that cardiac allograft vasculopathy (CAV) and graft failure are the major heart-related late mortality causes following HTx [1].
Source: International Journal of Cardiology - Category: Cardiology Authors: Tor Skibsted Clemmensen, Tim P. van de Hoef Tags: Editorial Source Type: research
More News: Bone Graft | Cardiology | Heart | Heart Failure | Heart Transplant | Lung Transplant | Transplant Surgery | Transplants